登录查看更多内容

NameTags PODCAST

Vishal Doshi

Founder, CEO @ AUM Biosciences | Board Member | Advisor | Investor & Inventor | Scientist | Passionate about building biotech companies

发布日期: 2020年8月5日

+ 关注

One of the interesting podcast with Solebury Trout Talks. It can be Found below

Solebury Trout Talks

About AUM

AUM is a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology. The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR).

要查看或添加评论，请登录

Vishal Doshi的更多文章

AUM Biosciences joins JLABS community:

2024年7月17日

AUM Biosciences joins JLABS community:

We are excited to share some remarkable news that marks a significant milestone in our journey towards advancing…

25 条评论
"Entrepreneurial Journey: Navigating the 'Life of Pi'"

2024年5月8日

"Entrepreneurial Journey: Navigating the 'Life of Pi'"

In the vast expanse of entrepreneurial exploration lies a treasure trove of wisdom waiting to be unearthed. Drawing…

2 条评论
Why Failing Matters and the Taboo Around Failure in Asia

2024年4月17日

Why Failing Matters and the Taboo Around Failure in Asia

I have had the pleasure to meet a lot of founders/ CEOs of start up & MNCs across different fields in the last 5 years…

4 条评论
Immunotherapies (Including MNK) to Address Unmet Medical Need in Cold Colorectal Cancer

2023年7月13日

Immunotherapies (Including MNK) to Address Unmet Medical Need in Cold Colorectal Cancer

Introduction: Colorectal cancer (CRC) is a significant global health concern, and while advancements in treatment have…

1 条评论
Small Molecule Drugs: Conquering Cancer Resistance

2023年7月8日

Small Molecule Drugs: Conquering Cancer Resistance

Introduction: Cancer resistance poses a significant challenge in achieving successful treatments. However, small…

1 条评论
Singapore’s renewed stake in the biomedical sciences sector

2020年9月7日

Singapore’s renewed stake in the biomedical sciences sector

As Singapore regains control in the fight against COVID-19, the impact on the economy remains severe. Close to $100…
AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies

2020年8月18日

AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies

As posted on: https://www.linkedin.

4 条评论
AUM Biosciences to Present at the Upcoming 2020 Summer Private Company Showcase

2020年8月6日

AUM Biosciences to Present at the Upcoming 2020 Summer Private Company Showcase

AUM Biosciences, a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering…

1 条评论
Singapore Launches Resilience Budget

2020年3月26日

Singapore Launches Resilience Budget

Some Highlights are below. Not a comprehensive summary.
My Interview with PHARMA Boardroom

2019年12月9日

My Interview with PHARMA Boardroom

The original interview can be found on…

See all articles

NameTags PODCAST

Vishal Doshi

Founder, CEO @ AUM Biosciences | Board Member | Advisor | Investor & Inventor | Scientist | Passionate about building biotech companies

Vishal Doshi的更多文章

社区洞察

其他会员也浏览了

Applied BioSciences Outlines Key Value Driving Opportunities Expected in 2020 and Focus on Advancing BioPharma Pipeline with The Stock Day Podcast

Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston

Recruitment of ASO technology expert as SAB, Improvement of development cost efficiency through KDDF project

FDA OKs First Biosimilar to Treat Cancer

A Deep Dive into the New Nimbus Therapeutics Website

Cell Expansion Market - Global Industry Trends Analysis 2019 to 2024

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Relief Therapeutics - Initiation of Coverage

BioLineRx acquires Kode immuno oncotherapeutic licensee Agalimmune

#JBS, #singlearm, #Bayesian

Vishal Doshi的更多文章

AUM Biosciences joins JLABS community:

"Entrepreneurial Journey: Navigating the 'Life of Pi'"

Why Failing Matters and the Taboo Around Failure in Asia

Immunotherapies (Including MNK) to Address Unmet Medical Need in Cold Colorectal Cancer

Small Molecule Drugs: Conquering Cancer Resistance

Singapore’s renewed stake in the biomedical sciences sector

AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies

AUM Biosciences to Present at the Upcoming 2020 Summer Private Company Showcase

Singapore Launches Resilience Budget

My Interview with PHARMA Boardroom

社区洞察

其他会员也浏览了

Applied BioSciences Outlines Key Value Driving Opportunities Expected in 2020 and Focus on Advancing BioPharma Pipeline with The Stock Day Podcast

Syntekabio to Showcase Biologics Discovery Platform at PEGS Boston

Recruitment of ASO technology expert as SAB, Improvement of development cost efficiency through KDDF project

FDA OKs First Biosimilar to Treat Cancer

A Deep Dive into the New Nimbus Therapeutics Website

Cell Expansion Market - Global Industry Trends Analysis 2019 to 2024

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: Mid-Week Update

Relief Therapeutics - Initiation of Coverage

BioLineRx acquires Kode immuno oncotherapeutic licensee Agalimmune

#JBS, #singlearm, #Bayesian